Connect with us

Business

Germany unveils scaled-down recreational cannabis legalization plan

Published

on

The German government is backpedaling on its plan to implement nationwide recreational cannabis legalization, instead opting for a two-track, scaled-down approach with limited commercial opportunities – for now.

Germany’s new blueprint for a regulated cannabis industry, unveiled Wednesday, features two pillars:

Germany is the latest country to scrap, postpone or otherwise present significantly watered-down cannabis legalization plans after originally promising full-scale legalization.

These policy pivots offer an important lesson to businesses on the importance of acting strategically and not reflexively.

Israel, Mexico and New Zealand have all unveiled ambitions to legalize and regulate adult-use cannabis in recent years, only to see those plans fizzle out for various reasons.

After unveiling a blueprint in October 2022, Germany’s draft framework was sent to the European Commission, the European Union’s executive branch, for approval to ensure compatibility with EU and global drug laws.

It’s clear that process did not go to according to plan for the current German government.

Germany’s government said it agreed to rethink its cannabis legalization blueprint after discussions with the EU Commission and taking international law into account.

The new scaled-back plan aims to:

  • Control quality.
  • Prevent the transfer of contaminated substances.
  • Protect minors.
  • Protect the health of consumers.
  • Curb the black market.

Germany’s federal government said it intends to present a draft law to parliament soon in addition to continuing efforts to promote the German approach of cannabis regulation to its European partners, particularly through missions abroad.

In the medium term, Germany is also examining the extent to which a sufficient number of EU-member countries could initiate their own cannabis regulation initiatives to comply with the relevant EU legal framework.

“The previous restrictive handling of cannabis in Germany has failed,” Federal Minister of Justice Marco Buschmann said in a news release.

“It’s time for a new approach that allows more personal responsibility, pushes back the black market and relieves the police and public prosecutor’s offices.”

‘Reality check’

Marla Luther, chief strategy officer at Avextra, a medical cannabis company in Germany, said the country was restricted by EU treaties in a way that Canada wasn’t when it legalized recreational cannabis in 2018.

Germany’s hands were tied because it’s part of the Schengen-area countries, which don’t have border controls.

“This was the biggest challenge on the European level – upholding the Schengen rules,” Luther said in an interview with MJBizDaily.

Avextra, a medical cannabis company with roots in plant-based medicine, is on a path to evidence-based cannabis medicines, similar to United Kingdom-based GW Pharma.

The Bensheim-headquartered company cultivates cannabis in Portugal and focuses on extracts-based innovation in Germany, where it sells into the medical market.

“The Germans have now found a way to figure out how to make this possible and still be compatible with EU treaties,” Luther said. “Maybe they were too robust in what they thought they could get through with the (EU Commission).

“They’ve had quite a reality check with (the EU Commission).

“There has to be a European-wide legal framework in order to make it possible. I think what you’re going to see now is Germany working a lot closer at the EU level to get a coalition together of seven countries or more.

‘Two-column’ model

Under the legalization plan Germany presented Wednesday, the nonprofit associations allowing personal cultivation and possession would be evaluated after four years.

If need be, this plan could be adjusted to account for issues related to health and youth protection as well as combating the illicit market.

Penalty-free possession would be allowed for personal consumption of up to 25 grams of cannabis.

Under narrow, clearly defined legal frameworks (which have not yet been determined), the associations would be able to jointly cultivate cannabis for recreational purposes for members to consume.

Commissioning third parties outside the association for cultivation would not be allowed, the government said.

Approval and monitoring would be carried out by state authorities, according to the news release, including compliance with quantity, quality and youth protection specifications and on-site inspections.

The German government said it might ban membership in more than one association.

Other details include:

  • Up to three female flowering plants would be allowed for home cultivation.
  • The number of members per association could be capped at 500, with a minimum age of 18. Members would have to live in Germany.
  • Reporting and documentation would be required for the quantities produced and delivered.
  • Membership fees would cover the association’s expenses.
  • The possibility of importing seeds from third-party countries for the associations is being examined.
  • A general advertising ban would be imposed on associations and for cannabis, but the government said “factual information” is acceptable.

The second pillar will focus on regional pilot projects with commercial supply chains.

Luther, the Avextra executive, said the key for the recreational-focused industry would be to see how strong the key performance indicators are for the proposed regional trial programs.

“At the end of the day, the biggest issue is going to be how big or small these model regions will be, and that’s how you know whether the business model is going to work,” she said.

The German government characterizes this pillar as “the next step on the way to a nationwide regulation,” according to the release, implying full legalization could still occur in the future.

The public policy goal of this step would be to create and collect data to scientifically examine the effects of a commercial supply chain on public health and youth protection as well as the illicit market.

Details for this pillar weren’t as fleshed out as they were for the nonprofit pillar.

Some key points include:

  • The project duration is expected to last five years.
  • Approval of the sale of edibles is being examined.
  • The trial would be scientifically monitored and evaluated, and the results will be shared with European partners and the EU Commission.

Source: https://mjbizdaily.com/germany-unveils-scaled-down-recreational-cannabis-legalization-plan/

Business

New Mexico cannabis operator fined, loses license for alleged BioTrack fraud

Published

on

New Mexico regulators fined a cannabis operator nearly $300,000 and revoked its license after the company allegedly created fake reports in the state’s traceability software.

The New Mexico Cannabis Control Division (CCD) accused marijuana manufacturer and retailer Golden Roots of 11 violations, according to Albuquerque Business First.

Golden Roots operates the The Cannabis Revolution Dispensary.

The majority of the violations are related to the Albuquerque company’s improper use of BioTrack, which has been New Mexico’s track-and-trace vendor since 2015.

The CCD alleges Golden Roots reported marijuana production only two months after it had received its vertically integrated license, according to Albuquerque Business First.

Because cannabis takes longer than two months to be cultivated, the CCD was suspicious of the report.

After inspecting the company’s premises, the CCD alleged Golden Roots reported cultivation, transportation and sales in BioTrack but wasn’t able to provide officers who inspected the site evidence that the operator was cultivating cannabis.

In April, the CCD revoked Golden Roots’ license and issued a $10,000 fine, according to the news outlet.

The company requested a hearing, which the regulator scheduled for Sept. 1.

At the hearing, the CCD testified that the company’s dried-cannabis weights in BioTrack were suspicious because they didn’t seem to accurately reflect how much weight marijuana loses as it dries.

Company employees also poorly accounted for why they were making adjustments in the system of up to 24 pounds of cannabis, making comments such as “bad” or “mistake” in the software, Albuquerque Business First reported.

Golden Roots was fined $298,972.05 – the amount regulators allege the company made selling products that weren’t properly accounted for in BioTrack.

The CCD has been cracking down on cannabis operators accused of selling products procured from out-of-state or not grown legally:

Golden Roots was the first alleged rulebreaker in New Mexico to be asked to pay a large fine.

Source: https://mjbizdaily.com/new-mexico-cannabis-operator-fined-loses-license-for-alleged-biotrack-fraud/

Continue Reading

Business

Marijuana companies suing US attorney general in federal prohibition challenge

Published

on

Four marijuana companies, including a multistate operator, have filed a lawsuit against U.S. Attorney General Merrick Garland in which they allege the federal MJ prohibition under the Controlled Substances Act is no longer constitutional.

According to the complaint, filed Thursday in U.S. District Court in Massachusetts, retailer Canna Provisions, Treevit delivery service CEO Gyasi Sellers, cultivator Wiseacre Farm and MSO Verano Holdings Corp. are all harmed by “the federal government’s unconstitutional ban on cultivating, manufacturing, distributing, or possessing intrastate marijuana.”

Verano is headquartered in Chicago but has operations in Massachusetts; the other three operators are based in Massachusetts.

The lawsuit seeks a ruling that the “Controlled Substances Act is unconstitutional as applied to the intrastate cultivation, manufacture, possession, and distribution of marijuana pursuant to state law.”

The companies want the case to go before the U.S. Supreme Court.

They hired prominent law firm Boies Schiller Flexner to represent them.

The New York-based firm’s principal is David Boies, whose former clients include Microsoft, former presidential candidate Al Gore and Elizabeth Holmes’ disgraced startup Theranos.

Similar challenges to the federal Controlled Substances Act (CSA) have failed.

One such challenge led to a landmark Supreme Court decision in 2005.

In Gonzalez vs. Raich, the highest court in the United States ruled in a 6-3 decision that the commerce clause of the U.S. Constitution gave Congress the power to outlaw marijuana federally, even though state laws allow the cultivation and sale of cannabis.

In the 18 years since that ruling, 23 states and the District of Columbia have legalized adult-use marijuana and the federal government has allowed a multibillion-dollar cannabis industry to thrive.

Since both Congress and the U.S. Department of Justice, currently headed by Garland, have declined to intervene in state-licensed marijuana markets, the key facts that led to the Supreme Court’s 2005 ruling “no longer apply,” Boies said in a statement Thursday.

“The Supreme Court has since made clear that the federal government lacks the authority to regulate purely intrastate commerce,” Boies said.

“Moreover, the facts on which those precedents are based are no longer true.”

Verano President Darren Weiss said in a statement the company is “prepared to bring this case all the way to the Supreme Court in order to align federal law with how Congress has acted for years.”

While the Biden administration’s push to reschedule marijuana would help solve marijuana operators’ federal tax woes, neither rescheduling nor modest Congressional reforms such as the SAFER Banking Act “solve the fundamental issue,” Weiss added.

“The application of the CSA to lawful state-run cannabis business is an unconstitutional overreach on state sovereignty that has led to decades of harm, failed businesses, lost jobs, and unsafe working conditions.”

Source: https://mjbizdaily.com/marijuana-companies-suing-us-attorney-general-to-overturn-federal-prohibition/

Continue Reading

Business

Alabama to make another attempt Dec. 1 to award medical cannabis licenses

Published

on

Alabama regulators are targeting Dec. 1 to award the first batch of medical cannabis business licenses after the agency’s first two attempts were scrapped because of scoring errors and litigation.

The first licenses will be awarded to individual cultivators, delivery providers, processors, dispensaries and state testing labs, according to the Alabama Medical Cannabis Commission (AMCC).

Then, on Dec. 12, the AMCC will award licenses for vertically integrated operations, a designation set primarily for multistate operators.

Licenses are expected to be handed out 28 days after they have been awarded, so MMJ production could begin in early January, according to the Alabama Daily News.

That means MMJ products could be available for patients around early March, an AMCC spokesperson told the media outlet.

Regulators initially awarded 21 business licenses in June, only to void them after applicants alleged inconsistencies with how the applications were scored.

Then, in August, the state awarded 24 different licenses – 19 went to June recipients – only to reverse themselves again and scratch those licenses after spurned applicants filed lawsuits.

A state judge dismissed a lawsuit filed by Chicago-based MSO Verano Holdings Corp., but another lawsuit is pending.

Source: https://mjbizdaily.com/alabama-plans-to-award-medical-cannabis-licenses-dec-1/

Continue Reading

Trending

Copyright © 2022 420 Reports Marijuana News & Information Website | Reefer News | Cannabis News